Samjin Pharmaceutical in the top 50 among the traditional pharmaceutical companies… 12 companies recorded double-digit operating margins
Of the 662 corporations (excluding the financial sector) whose closing account is at the end of December in the KOSPI market, nine companies in the pharmaceutical sector ranked in the top 100 in operating margin in the third quarter.
According to the data from the Korea Exchange, 12 out of 42 companies in the pharmaceutical industry recorded double-digit operating margins.
Six companies entered the top 50 out of 662 in the securities market with an operating margin exceeding 20%, while nine companies, including the six, ranked in the top 100.
Celltrion posted the largest operating margin of 47.34%, ranking 20th, followed by SK Bioscience (21st) with 45.47%, and Chong Kun Dang Holdings (25th) with 41.15%, exceeding 40%.
Pharmicell ranked 44th with 25.81%, Samjin Pharmaceutical 46th with 24.87%, and six companies entered the top 50 with over 20% of operating margins.
Meanwhile, Samjin Pharmaceutical was the only traditional pharmaceutical company (excluding holding companies) to rank in the top 50.
Nine companies with above 16% or higher were ranked in the top 100, including Whanin Pharmaceutical in 78th with 18.31%, Green Cross Corporation in 85th with 17.13%, and Hana Pharm in 91st with 16.53%.
Korea United Pharmaceuticals was placed 103rd with 15.05%, Boryung Pharmaceutical 134th with 11.72%, and Chong Kun Dang Pharmaceutical 1501st with 10.85%.
In the top 200, with 9-percent operating margins, Bukwang Pharmaceutical was at 182nd with 9.31%, and Daewoong Pharmaceutical at 189th with 9.02%
Companies exceeding 7% of operating margins, including Daewon Pharmaceutical, Il-Yang Pharmaceutical, Hanmi Pharmaceutical, HanAll Biopharma, and Dong-A ST entered the top 300, and Handok, Kwang Dong Pharmaceutical, and JW Pharmaceutical ranked in the top 300 with 5% range.
Dongwha Pharm, Ildong Holdings, PharmGen Science, and Kukje Pharma, which recorded an operating margin of more than 2%, were in the top 400.
Moreover, Yuhan Corporation, Samil Pharmaceutical, Myungmoon Pharm., Jeil Pharmaceutical, and Reyon Pharmaceutical remained less than 2%, while Yuyu Pharma, Aprogen Pharmaceuticals, Ilsung Pharmaceutical, Dongsung Pharmaceutical, CKD Bio, Yungjin Pharmaceuticals, Kyongbo Pharmaceutical, Ildong Pharmaceutical, Shinpoong Pharmaceutical, Samsung Pharm., and GeneOne Life Science recorded deficits.